Free Newsletter
Pharma plots Democratic course
With Democrats in control of the White House and Congress, Big Pharma leaders are busy planning how the industry will work with this new wave of politicians. President-elect Obama and other Democrats are looking to overhaul the country's healthcare system, which they say has grown far too costly and leaves over 45 million people uninsured. Democrats aren't pleased with the pharma industry's high drug prices, aggressive marketing and drug safety problems either. But leaders like Schering-Plough CEO Fred Hassan (photo) and Bayer CEO Arthur Higgins (photo) are stressing the need for Pharma to strengthen ties with the Democrats.
"[W]e're working very hard to build bridges...all we're asking for is we have some points to make. You don't have to accept those points, but we just ask you to listen. That's the beginning of a dialogue," noted Higgins. Pharma already laid the groundwork by donating heavily to Democrats during the campaign process.
An expanded healthcare system would benefit drug companies because it would give patients greater access to prescription drugs. On the flip side, however, the government could place pricing pressure on these drugs, which would cut into Big Pharma's bottom line. Industry group PHrMA is already planning a PR campaign touting the benefit of free-market healthcare system.
- read this Pharmalot article
Related Articles:
PhRMA poised to fight Obama plans
Generics makers anticipate Obama boon
How will Obama change pharma?
Comments
Post new comment
Paid Research Reports
- Stakeholder Opinions: Vaccines in Emerging Markets (Asia) - Opportunities in China, India, South Korea and Taiwan
- Big Pharma Performance Before, During and Beyond the Global Recession
- Optimizing Lifecycle Management: Maximizing commercial lifespan through label expansion and combination products
- The CRO Market Outlook: Emerging markets, leading players and future trends
- Pharmaceutical Sales Force Effectiveness Strategies
- Commercial Insight: Influenza Vaccines and Antivirals - The pandemic's long-term impact





